TX-WEA
27.10.2021 10:34:07 CEST | Business Wire | Press release
The Women’s Entrepreneurship Accelerator (WEA), a strategic multi-partnership convening five UN agencies and Mary Kay Inc., is today joining forces with the Commonwealth Businesswomen’s Network (CBWN) to empower and support underserved women entrepreneurs across the 54 countries of the Commonwealth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005291/en/
WEA is designed to maximize the development impact of women entrepreneurship in achieving the Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs that fosters growth, sustainability, and resilience. In June 2021, WEA joined the Generation Equality Forum in Paris and committed to empower five million women around the world by 2030 to accelerate progress for gender equality.
WEA recently announced the launch of a series of impactful initiatives and knowledge products, all shaped through a gender lens, as the joint outcome of the collaboration between the International Labour Organization (ILO), the International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP) and UN Women with the strategic support and funding of Mary Kay. WEA’s impact work includes digital capacity building tools and training; entrepreneurship research; and gender-responsive procurement (GRP) advocacy and training.
CBWN works with women in business by connecting governments and the private sector to encourage, enable and embed women’s economic empowerment and women in leadership. Originating in May 2021, the Commonwealth Women’s Entrepreneurship Accelerator (CWEA) is a strategic multi-stakeholder partnership from the CBWN, the Global Entrepreneurship Network UK (GEN UK) and Oxentia. It is a direct response to three developments: the agreement by all Commonwealth Heads of Government in London in 2018 “to work towards an increase in the number and enhancement of the success rate of women-owned businesses, break down gender barriers in all sectors, and increase opportunities for women to trade internationally”; the recognition by the G20 in 2020 that “there is a missed opportunity – to tackle the gap that needs immediate action, which is the representation of women in emerging fields”; and the UN Global Acceleration Plan to advance gender equality by 2026 and its Action Coalitions on Economic Justice and Rights and Technology and Innovation launched in 2021.
The new partnership with CBWN in support of CWEA further solidifies WEA’s geographic scope of action across the 54 Commonwealth diverse country members in Africa, Asia, the Americas, Europe, and the Pacific, with 32 countries classified as “small states.” Small states are especially vulnerable to climate change and developmental challenges including gender inequalities.
Beyond scaling WEA and CBWN’s foundational areas of work, the partnership will also significantly focus on policy and advocacy to advance systemic change engaging Commonwealth member states and leveraging its networks of organizations and key stakeholders in support of women in business or aspiring women entrepreneurs in and across the Commonwealth.
“We know that multi-stakeholder partnerships and collective engagement is crucial to drive the change that women entrepreneurs need across sectors around the world,” said Deborah Gibbins, Chief Operating Officer of Mary Kay Inc. “WEA is thrilled to join forces with the Commonwealth Businesswomen’s Network and the Commonwealth Women’s Entrepreneurship Accelerator. Our collaboration will focus on augmenting, amplifying and accelerating impact. We’re more powerful together, and I look forward to our collective action journey in support of the SDGs.”
“The Commonwealth Businesswomen’s Network is delighted to partner with the United Nations Women’s Entrepreneurship Accelerator in this landmark initiative so we can unlock and unleash the power and potential for more women of diverse backgrounds,” said Freda Miriklis, Chair, Commonwealth Businesswomen’s Network. “Through this partnership, we’ll be able to more quickly harness our collective assets - for women, their communities and every girl that can and will be inspired by their stories.”
To learn more about the Women’s Entrepreneurship Accelerator, visit we-accelerate.com .
About the Women’s Entrepreneurship Accelerator
The Women’s Entrepreneurship Accelerator (WEA) is a multi-partnership initiative on women’s entrepreneurship convening 5 UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP), UN Women and Mary Kay Inc. to empower 5 million women entrepreneurs by 2030.
The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs.
Learn more at we-accelerate . Follow us: Twitter (@We_Accelerator ), Instagram (@we_accelerator ), Facebook (@womensentrepreneurshipaccelerator ), LinkedIn (@womensentrepreneurshipaccelerator )
About the Commonwealth Businesswomen’s Network
The Commonwealth Businesswomen’s Network (CBWN) works with women in business by connecting Governments and the private sector to encourage, enable and embed women’s economic empowerment. This is achieved through delivering activities, initiatives, products, and services focused on trade, talent, and training. It is the only accredited organisation focused on women’s economic empowerment and directly recognized by 54 governments across six continents. Learn more at www.cbwn.org
About the Commonwealth Women’s Entrepreneurship Accelerator
The Commonwealth Women’s Entrepreneurship Accelerator is a strategic multi stakeholder partnership on women’s entrepreneurship established as an outcome of the inaugural Commonwealth Women’s Entrepreneurship Summit (CWES) in May 2021, the first global event to focus on women in emerging tech sectors. CWES was convened by the Commonwealth Businesswomen’s Network; the Global Entrepreneurship Network; the UK Government (Women in Innovation Network, a programme of Innovation UK); and Africa’s largest network of women entrepreneurs (AWEP: African Women’s Entrepreneurship Program). The Commonwealth Women’s Entrepreneurship Accelerator is a partnership between the Commonwealth Businesswomen’s Network, Global Entrepreneurship Network-UK and Oxentia. Learn more at www.thecwea.org
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 58 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements, and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at marykayglobal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005291/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
